Anxiolytic effects of a new triazolobenzodiazepine, U-31,889.
D000328:Adult; D000818:Animals; D001007:Anxiety / Q000188:drug therapy*; D001522:Behavior, Animal / Q000187:drug effects; D001570:Benzodiazepinones / Q000494:pharmacology / Q000627:therapeutic use*; D001775:Blood Circulation / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D003201:Computers; D003863:Depression / Q000188:drug therapy*; D004285:Dogs; D004569:Electroencephalography; D005260:Female; D005479:Flurazepam / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D012119:Respiration / Q000187:drug effects; D012640:Seizures / Q000188:drug therapy; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D014149:Tranquilizing Agents; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D001570:Benzodiazepinones; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D014230:Triazoles; D005479:Flurazepam